Liver Diseases  >>  brivanib alaninate (BMS-582664)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
brivanib alaninate (BMS-582664) / ZAI Lab
BRISK FL, NCT00858871 / 2008-003533-24: First Line Hepato Cellular Carcinoma (HCC)

Checkmark vs. sorafenib as first-line therapy
Aug 2013 - Aug 2013: vs. sorafenib as first-line therapy
Checkmark Anticipated P3 Data (1st line; HCC) BRISK FL
Jul 2012 - Jul 2012: Anticipated P3 Data (1st line; HCC) BRISK FL
Checkmark P3 data (Interim analysis; post sorafenib)
More
Completed
3
1714
Japan, US, Canada, Europe, RoW
Brivanib, BMS-582664, Placebo, Sorafenib
Bristol-Myers Squibb
Hepato Cellular Carcinoma (HCC)
06/12
09/13
BRISK-APS, NCT01108705: Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment

Terminated
3
87
RoW
Brivanib, BMS-582664, Placebo
Bristol-Myers Squibb
Carcinoma, Hepatocellular
10/13
10/13

Download Options